Wedbush Expects Higher Earnings for Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at Wedbush upped their FY2024 EPS estimates for Zentalis Pharmaceuticals in a research report issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($2.33) for the year, up from their prior forecast of ($2.83). Wedbush currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($3.02) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.66) EPS, Q1 2025 earnings at ($0.69) EPS, Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.48) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($1.67) EPS and FY2028 earnings at ($0.88) EPS.

ZNTL has been the topic of a number of other reports. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday. Finally, Guggenheim lowered their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, Zentalis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $10.00.

Zentalis Pharmaceuticals Stock Down 12.2 %

NASDAQ ZNTL opened at $3.47 on Friday. Zentalis Pharmaceuticals has a 12-month low of $2.66 and a 12-month high of $18.07. The company has a market capitalization of $247.29 million, a PE ratio of -1.39 and a beta of 1.74. The firm’s 50 day moving average is $3.42 and its 200-day moving average is $5.46.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ZNTL. Price T Rowe Associates Inc. MD boosted its position in Zentalis Pharmaceuticals by 20.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after purchasing an additional 585,644 shares during the period. Decheng Capital LLC raised its stake in Zentalis Pharmaceuticals by 46.2% in the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after purchasing an additional 970,859 shares in the last quarter. Verition Fund Management LLC raised its stake in Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after acquiring an additional 951,500 shares in the last quarter. Primecap Management Co. CA raised its stake in Zentalis Pharmaceuticals by 21.6% during the third quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after acquiring an additional 265,690 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in Zentalis Pharmaceuticals by 152.6% during the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after acquiring an additional 399,745 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.